Navigation Links
NIAID media availability: New strategy proposed for designing antibody-based HIV vaccine
Date:6/14/2009

WHAT: Most vaccines that protect against viruses generate infection-fighting proteins called antibodies that either block infection or help eliminate the virus before it can cause disease. Attempts to create a vaccine that induces antibodies that prevent HIV infection or disease, however, have so far been unsuccessful. But several recent studies suggest promising new research directions for the development of an antibody-based HIV vaccine, according to John R. Mascola, M.D., deputy director of the Vaccine Research Center at the National Institute of Allergy and Infectious Diseases of the National Institutes of Health, and colleagues.

These studies demonstrate that, contrary to widespread belief, it is not uncommon for people infected with HIV to naturally make antibodies that can neutralize a variety of HIV strains. These antibodies do not protect people from the virus because they arise years after HIV infection is established. However, if a vaccine could prime the body to make these broadly neutralizing antibodies before exposure to HIV, they could potentially prevent infection or hold the virus at bay until an army of immune cells assembles to limit viral replication.

Based on these findings, Dr. Mascola and colleagues recommend a research strategy that uses naturally occurring, broadly neutralizing anti-HIV antibodies for the ultimate design of an antibody-based HIV vaccine.

Key aspects of this strategy include

  • Obtaining new broadly neutralizing antibodies to HIV to expand the pool available for scientists to study
  • Identifying regions on the surface of HIV that are vulnerable to broadly neutralizing antibodies and determining the atomic-level crystal structure of those regions
  • Understanding how broadly neutralizing antibodies to HIV evolve and persist
  • Clarifying the structural differences between anti-HIV antibodies that do and do not have neutralizing properties
  • Determining what quantity of broadly neutralizing antibodies an HIV vaccine must elicit to be effective
  • Learning how anti-HIV neutralizing antibodies and HIV surface proteins evolve in response to one another in people who eventually produce a powerful neutralizing antibody response to the virus
  • Clarifying how HIV surface proteins are presented to the immune cells that produce broadly neutralizing antibodies to HIV
  • Determining what immune-system conditions promote the production of broadly neutralizing anti-HIV antibodies


'/>"/>

Contact: Laura Sivitz
sivitzl@niaid.nih.gov
301-402-1663
NIH/National Institute of Allergy and Infectious Diseases
Source:Eurekalert

Related medicine news :

1. J. Craig Venter Institute Awarded $43 Million, Five Year Contract From NIAID to Continue to Develop and Provide Sequencing, Genotyping, and Bioinformatics Expertise and Services in Infectious Diseases
2. NIAID and Chinese officials sign agreement to foster TB research in Chinas Henan province
3. NIAID honors AIDS activist Martin Delaney
4. NIAID media availability: Seizures following parasitic infection associated with brain swelling
5. NIAID awards contracts to search for protein markers of disease
6. NIAID creates HIV vaccine discovery branch
7. NIAID to advance B-cell approach to HIV vaccines
8. NIAID describes research priorities to fight drug-resistant tuberculosis
9. NIAID to convene HIV Vaccine Summit
10. NIAID scientists identify new cellular receptor for HIV
11. NIAID strengthens and expands Vaccine and Treatment Evaluation Units
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... CO (PRWEB) , ... January 17, 2017 , ... ... protection and financial planning assistance to families and business professionals throughout central Colorado, ... to regional homeless families. , The Aurora Warms The Night organization is committed ...
(Date:1/17/2017)... ... January 17, 2017 , ... ... survivor Sandra Lee as keynote speaker for the 34th Annual Miami Breast Cancer ... making the announcement, PER® president, Phil Talamo, said, “We are delighted to have ...
(Date:1/17/2017)... ... January 17, 2017 , ... Today, FloSports , a global ... a new agreement as part of a long-term extension of their media partnership. The ... airing of some of the sport’s premier events exclusively on FloWrestling.com as well as ...
(Date:1/16/2017)... ... January 16, 2017 , ... California Southern University has named Dr. ... CalSouthern’s Board of Trustees and as a core faculty member, teaching master’s and doctoral ... professor of psychology at Pepperdine University, where he earned his Doctor of Psychology degree ...
(Date:1/16/2017)... ... January 16, 2017 , ... Anybody who may be looking for ... new video released by Serenity Recovery, a holistic treatment center for addiction located in ... features footage and testimonials from patients and staff that visited the 2016 Recovery Palooza ...
Breaking Medicine News(10 mins):
(Date:1/17/2017)... -- In a letter to President-elect Donald J. Trump ... AARP,s priorities for Americans age 50 and older including ... health care coverage, and lowering the cost of prescription ... President-elect Trump that "Our nearly 38 million members nationwide ... protect their Medicare and Social Security benefits, protect their ...
(Date:1/17/2017)... , Jan. 17, 2017   Anesthesia ... billing and practice management for the anesthesia and ... marijuana, which remains a "clinical conundrum" (as described ... chronic pain practitioners to think carefully before recommending ... 395-page report by the National Academies of Sciences, ...
(Date:1/17/2017)... NEW YORK , Jan. 17, 2017 ... clinical stage biopharmaceutical company, announced today that it will ... International Symposium on Acute Leukemias (ISAL) XVI in ... symposium is entitled:  "Reinforcing the Efficacy of Immunotherapy for ... will take place on Monday February 20 th , 2017 ...
Breaking Medicine Technology: